Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/03/2023* 08:30 EST Earnings Call Q4 2022 -- -- --
03/03/2023* -- Results Q4 2022 -- -0.17 --
11/09/2022 -- Results Q3 2022 -0.16 -0.25 34.69%
11/09/2022 08:30 EST Earnings Call Q3 2022 -- -- --
08/03/2022 08:30 EST Earnings Call Q2 2022 -- -- --
08/03/2022 -- Results Q2 2022 -0.25 -0.28 10.71%
04/28/2022 08:30 EST Earnings Call Q1 2022 -- -- --
04/28/2022 -- Results Q1 2022 -0.28 -0.32 11.11%
*Estimated Date/Time

Earnings

Next Report Date 03/03/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/09/2022
Beat/Miss Upgrade
Return Since 276.7%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
URL https://www.glycomimetics.com
Investor Relations URL http://ir.glycomimetics.com/
HQ State/Province Maryland
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 03, 2023 (est.)
Last Earnings Release Nov. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
6.64%
175.2%
-43.60%
-44.14%
-28.92%
-61.70%
110.4%
1.98%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
7.86%
--
--
--
83.39%
80.15%
12.18%
11.66%
-4.57%
--
--
-73.55%
-24.54%
83.74%
-82.15%
-36.94%
-53.92%
-28.42%
47.06%
-66.67%
71.67%
-17.67%
236.8%
-15.76%
-82.79%
-44.00%
-72.79%
-73.12%
95.56%
154.5%
-72.78%
-90.18%
10.49%
As of February 03, 2023.

Profile

Edit
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
URL https://www.glycomimetics.com
Investor Relations URL http://ir.glycomimetics.com/
HQ State/Province Maryland
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 03, 2023 (est.)
Last Earnings Release Nov. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter GLYC Tweets